A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs | Blood | American Society of Hematology

Asciminib demonstrated superior efficacy (MMR at week 24 was 25.5% v. 13.2%) and tolerability (50.6% vs 60.5% >G3 AEs) compared to bosutinib in patients with chronic phase CML after at least 2 prior TKIs.

Read the full article here

Related Articles